Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Upstream Bio (UPB) EPS (Weighted Average and Diluted) (2023 - 2025)

Upstream Bio has reported EPS (Weighted Average and Diluted) over the past 3 years, most recently at -$0.78 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.78 for Q4 2025, down 106.21% from a year ago — trailing twelve months through Dec 2025 was -$2.66 (up 52.24% YoY), and the annual figure for FY2025 was -$2.66, up 52.33%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.78 at Upstream Bio, down from -$0.63 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for UPB hit a ceiling of $12.57 in Q4 2024 and a floor of -$6.96 in Q3 2024.
  • Median EPS (Weighted Average and Diluted) over the past 3 years was -$1.44 (2023), compared with a mean of -$1.54.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 348.91% in 2024, while the deepest fall reached 229.86% in 2024.
  • Upstream Bio's EPS (Weighted Average and Diluted) stood at -$5.05 in 2023, then surged by 348.91% to $12.57 in 2024, then crashed by 106.21% to -$0.78 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.78 (Q4 2025), -$0.63 (Q3 2025), and -$0.74 (Q2 2025) per Business Quant data.